Company: PSTV
Filing Date: 2025-04-23
Form Type: S-3/A
Source: 0001193125-25-091456
Chunk: 8

Company: PLUS THERAPEUTICS, INC.
Filing Date: 2025-04-23
Form: S-3/A
Chunk 8
---
US SUMMARY

This summary highlights selected information from this prospectus and may not contain all of the information that is important to you in making your investment decision. Before investing in our shares of common stock, you should carefully read the entire prospectus, including the information set forth under the heading “Risk Factors” and the financial statements and related notes and other information that we incorporate by reference herein, including our Annual Report on Form 10-Kand our Quarterly Reports on Form 10-Q.See also the sections entitled “Where You Can Find Additional Information” and “Incorporation by Reference.” Unless the context indicates otherwise, references in this prospectus to “Plus Therapeutics,” “we,” “our” and “us” refer, collectively, to Plus Therapeutics, Inc., a Delaware corporation, and its subsidiary taken as a whole.

Our Company

Overview

Plus Therapeutics is a
U.S. pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (“CNS”) cancers. Our novel radioactive drug formulations, medical devices and therapeutic candidates are
designed to deliver safe and effective doses of radiation to tumors. To achieve this, we have developed innovative approaches to drug formulation, including encapsulating radionuclides such as rhenium isotopes with nanoliposomes and microspheres.
Our formulations are intended to achieve elevated patient-absorbed radiation doses and extend retention times such that the clearance of the isotope occurs after significant and essentially complete radiation decay, which will contribute and provide
less normal tissue/organ exposure and improved safety margins.

Our lead radiotherapeutic candidate,
REYOBIQ (rhenium (186Re) obisbemeda), is designed specifically for CNS cancers including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers by direct localized
delivery utilizing approved standard-of-care tissue access such as with convection-enhanced delivery and intraventricular brain (Ommaya reservoir) catheters. Our
acquired radiotherapeutic candidate, Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere is designed to treat many solid organ cancers including primary and secondary liver cancers by intra-arterial
injection.

On April 26, 2024, we acquired the cerebrospinal fluid cancer diagnostic portfolio known as the “CNSide Platform” that is currently being utilized in the ReSPECT-LM clinical trial funded by the Cancer Prevention and Research Institute of Texas. We are
planning for